What's breaking now, across thousands of outlets.
Plus news about Genmab, Rumi, Prana and Fractyl. Outpace Bio ends cell therapy trial: The Seattle startup canned a Phase 1 ovarian cancer trial of its mesothelin autologous CAR-T, called OPB-101 ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.
Last year, U.K. gene therapy startup Bloomsbury Genetic Therapies announced it was shutting down after dosing just one patient. Now, a nonprofit is resurrecting its lead program:
The affected individuals comprise 51 students and two staff members. None were hospitalised.
The affected individuals comprise 51 students and two staff members. None were hospitalised.
(MedPage Today) -- The fast-moving Ebola outbreak in Congo has reached 10,000 confirmed cases, government data showed Tuesday, as health authorities race to slow the spread of the disease in multiple…
Who will steer the World Health Organization through its next chapter? Explore Health Policy Watch’s daily series examining the platforms, records, and institutional hurdles facing each contender for…
Its not known if there were prior complications before her death or how long the woman had been in Costa Rica.
